A prospective study of treatment continuation rate with early low-dose iron chelation therapy for patients with transfusion-induced iron overload
Not Applicable
- Conditions
- Transfusion-induced iron overload
- Registration Number
- JPRN-UMIN000007644
- Lead Sponsor
- Osaka Saiseikai Nakatsu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with simultaneous multiple cancers. (2) Patients with severe liver or severe renal dysfunction. (3) Pregnant women or those with suspected pregnancy or nursing women (4) Patients with a psychiatric illness or symptoms that make it difficult to participate in the study. (5) Patients with history of hyper sensitivity to deferasirox. (6) Patients with history of hematopoietic stem cell transplantation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment continuation rate at 12 months after the initiation of iron chelation therapy
- Secondary Outcome Measures
Name Time Method (1) Changes of serum ferritin (2) Achievement rate of SF<1,000 (3) Achievement rate of SF<2,500 (4) Improvement of organ failure (heart, liver, pancreas) (5) Safety (6) Hematopoietic improvement (IWG2006 criteria) (7) total dose of transfusions (8) Concentration of EPO (9) Exposure of deferasirox